KCNK2 Protein (TREK-1 Potassium Channel)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">KCNK2 Protein (TASK-1 Potassium Channel)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[KCNK2](/genes/kcnk2)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[O95069](https://www.uniprot.org/uniprot/O95069)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~56 kDa (each subunit)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Plasma membrane</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Two-pore domain potassium (K2P) channel family</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>TASK1, K2P2.1, TREK-1, TWIK-related potassium channel 1</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>Homodimer, 4 transmembrane domains per subunit</td>
</tr>
<tr>
<td class="label">Ion Selectivity</td>
<td>K+ selective</td>
</tr>
<tr>
<td class="label">Channel Type</td>
<td>Leak/background potassium channel</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a>, <a href="/wiki/autism" style="color:#ef9a9a">Autism</a>, <a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-9eae33ba" style="c
...KCNK2 Protein (TREK-1 Potassium Channel)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">KCNK2 Protein (TASK-1 Potassium Channel)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[KCNK2](/genes/kcnk2)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[O95069](https://www.uniprot.org/uniprot/O95069)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~56 kDa (each subunit)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Plasma membrane</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Two-pore domain potassium (K2P) channel family</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>TASK1, K2P2.1, TREK-1, TWIK-related potassium channel 1</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>Homodimer, 4 transmembrane domains per subunit</td>
</tr>
<tr>
<td class="label">Ion Selectivity</td>
<td>K+ selective</td>
</tr>
<tr>
<td class="label">Channel Type</td>
<td>Leak/background potassium channel</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a>, <a href="/wiki/autism" style="color:#ef9a9a">Autism</a>, <a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-9eae33ba" style="color:#ce93d8" title="Score: 0.42">Aquaporin-4 Polarization Enhancement via...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">348 edges</a></td>
</tr>
</table>
:: infobox .infobox-protein
:::
Overview
TREK-1 (TWIK-related potassium channel 1), encoded by the [KCNK2](/genes/kcnk2) gene, is a member of the two-pore domain potassium (K2P) channel family that regulates background leak currents and neuronal excitability[@patel2001]. These channels play critical roles in maintaining the resting membrane potential and responding to physiological and pathological stimuli. KCNK2 is widely expressed in the brain and has been implicated in various neurological conditions including epilepsy, migraine, depression, and neurodegenerative diseases[@honore2007].
Structure
KCNK2 (TREK-1) is a two-pore domain potassium channel with distinctive structural features:
- Subunit architecture: Each subunit contains four transmembrane segments (M1-M4) and two pore domains (P1 and P2)[@lesage2000]
- Dimeric assembly: Functional channels are homodimers, creating the characteristic two-pore structure
- Topology: Intracellular N- and C-termini with two extracellular loops containing the selectivity filter
- Molecular weight: Approximately 56 kDa per subunit
The channel's structural arrangement creates a K+-selective pore that conducts leak currents at negative membrane potentials. This architecture distinguishes K2P channels from voltage-gated potassium (Kv) channels which have a single pore per subunit[@miller2012].
Mechanism of Activation
TREK-1 responds to multiple physiological stimuli through distinct activation mechanisms:
Mechanical Activation
- Membrane stretch deformation directly opens the channel
- Cytoskeletal involvement in mechanotransduction
- Rapid response to cellular edema during ischemia
Thermal Activation
- Temperature coefficient indicating heat activation above 37°C
- Contributes to thermal sensation in [neurons](/entities/neurons)
Chemical Activation
- Polyunsaturated fatty acids (arachidonic acid, docosahexaenoic acid)[@maingret1999]
- Phospholipids including PIP2
- Volatile anesthetics
pH Modulation
- Intracellular pH affects gating
- Alkaline pH increases activity
Cellular and Tissue Distribution
Brain Expression
TREK-1 shows widespread CNS expression:
- [Hippocampus](/brain-regions/hippocampus): CA1 pyramidal cells, dentate gyrus granule cells
- Cerebral [cortex](/brain-regions/cortex): Layer V pyramidal neurons
- Basal ganglia: Striatal medium spiny neurons
- Thalamus: Relay neurons
- Hypothalamus: Neuroendocrine cells
- Brainstem: Raphe nuclei, locus coeruleus
Peripheral Expression
- Heart: Cardiac myocytes
- Skeletal muscle: Muscle spindles
- Peripheral neurons: Dorsal root ganglion sensory neurons
- Smooth muscle: Vascular and gastrointestinal
Role in Neurodegeneration
Ischemic Stroke and Neuroprotection
TREK-1 activation mediates neuroprotective responses during ischemic stroke. Mechanical stress from edema activates TREK-1 channels, producing hyperpolarization that reduces [NMDA receptor](/entities/nmda-receptor)-mediated excitotoxicity[@heurteaux2004]. TREK-1 knockout mice show larger infarcts following middle cerebral artery occlusion.
Epilepsy
Altered TREK-1 expression contributes to hyperexcitability in epilepsy. Seizure-induced mechanical and chemical changes affect TREK-1 function. Human epilepsy tissue shows reduced TREK-1 expression in seizure foci[@pang2009].
Depression
TREK-1 was the first ion channel directly linked to major depressive disorder. Antidepressant drugs including selective serotonin reuptake inhibitors (SSRIs) inhibit TREK-1. TREK-1 knockout mice exhibit antidepressant-like phenotypes[@luckhart2021].
Pain Processing
TREK-1 in sensory neurons modulates mechanical and thermal pain thresholds. The channel contributes to mechano-sensitive pain pathways and represents a target for novel analgesics[@alloui2006].
Alzheimer's Disease
Emerging evidence suggests K2P channel dysfunction in Alzheimer's disease. [Amyloid-beta](/proteins/amyloid-beta) peptides interact with neuronal membranes to alter TREK-1 gating, potentially contributing to excitability changes in AD[@berson2022].
Parkinson's Disease
Preliminary studies suggest TREK-1 expression changes in substantia nigra dopaminergic neurons in PD models. Further research is needed to clarify the role.
Signaling Pathways
TREK-1 is modulated by multiple intracellular signaling mechanisms:
- G protein coupling: Gq-coupled receptor activation (muscarinic, bradykinin)
- Phosphorylation: PKC-mediated phosphorylation reduces activity
- Lipid signaling: PIP2 requirement for channel function
- Calmodulin: Calcium-calmodulin modulates gating
- Nitric oxide: Direct modulation through S-nitrosylation
Therapeutic Targets
Neuroprotective Agents
TREK-1 activators are being developed for stroke and traumatic brain injury treatment. Lead compounds have shown efficacy in preclinical models[@heurteaux2004].
Antidepressants
Understanding TREK-1 inhibition by existing antidepressants informs novel drug development. Selective TREK-1 modulators may offer alternatives to current treatments[@luckhart2021].
Analgesics
TREK-1 activators could provide analgesia through peripheral sensory neuron modulation without opioid liabilities[@alloui2006].
Anti-ischemic Agents
Direct TREK-1 activators represent a novel approach to reduce excitotoxic damage following stroke.
Clinical Relevance
Biomarkers
- TREK-1 expression levels in patient tissue samples
- Functional electrophysiological assays
- Genetic polymorphisms and treatment response
Drug Development
- High-throughput screening for TREK-1 activators
- Structure-activity relationship optimization
- [Blood-brain barrier](/entities/blood-brain-barrier) penetration considerations
Research Methods
Key experimental approaches:
Electrophysiology: Inside-out and whole-cell patch-clamp recording
Expression analysis: qRT-PCR, Western blot, immunohistochemistry
Behavioral testing: Mechanical allodynia, thermal hyperalgesia assays
Calcium imaging: Neuronal excitability changes
Animal models: Conditional and global knockout miceInteractions and Associated Proteins
TREK-1 interacts with:
- PIP2: Essential phospholipid cofactor
- Calmodulin: Calcium-dependent modulation
- PKC: Phosphorylation regulation
- Filamin A: Cytoskeletal anchoring
- GRIP1: Scaffold protein interactions
See Also
- [KCNK2 Gene](/genes/kcnk2)
- [KCNK3 Protein (TASK-1 Potassium Channel)](/proteins/kcnk3-protein)
- [K2P Potassium Channels](/mechanisms/potassium-channels)
- [Two-Pore Domain Channels](/mechanisms/two-pore-domain-channels)
- [Excitotoxicity](/mechanisms/excitotoxicity)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
External Links
- [UniProt: O95069](https://www.uniprot.org/uniprot/O95069)
- [NCBI Protein: KCNK2](https://www.ncbi.nlm.nih.gov/protein/NP_001026593)
- [IUPHAR/BPS Guide to Pharmacology: TREK-1](https://www.guidetopharmacology.org/GRAC/receptorDisplayForward?receptorId=2379)
References
[Patel AJ, Lazdunski M, Honore E, Lipid and mechano-sensitivity of two-pore domain K+ channels (2001)](https://pubmed.ncbi.nlm.nih.gov/11376021/)
[Honore E, The neuronal background K2P channels: from basic physiology to disease (2007)](https://pubmed.ncbi.nlm.nih.gov/16715079/)
[Lesage F, Lazdunski M, Molecular and functional properties of two-pore-domain potassium channels (2000)](https://pubmed.ncbi.nlm.nih.gov/11053082/)
[Miller AN, Long SB, Crystal structure of the potassium channel KirBac1.1 in the closed state (2012)](https://pubmed.ncbi.nlm.nih.gov/22619250/)
[Maingret F, Patel AJ, Lesage F, et al, Mechano- or acid stimulation, two interactive modes of activation of the TREK-1 potassium channel (1999)](https://pubmed.ncbi.nlm.nih.gov/10480839/)
[Heurteaux C, Guy N, Laigle C, et al, TREK-1, a K+ channel involved in neuroprotection and general anesthesia (2004)](https://pubmed.ncbi.nlm.nih.gov/15215894/)
[Pang DS, Robelet C, Guglielmetti C, et al, Altered expression of TASK-1 and TASK-3 in rat and human temporal lobe epilepsy (2009)](https://pubmed.ncbi.nlm.nih.gov/19515949/)
[Luckhart C, Liedtke WB, Ghose S, The role of TREK-1 in depression and antidepressant action (2021)](https://pubmed.ncbi.nlm.nih.gov/33157090/)
[Alloui A, Zimmermann K, Mamet J, et al, TREK-1, a K+ channel involved in polymodal pain perception (2006)](https://pubmed.ncbi.nlm.nih.gov/16688217/)
[Berson A, Puri A, Ravid D, et al, Lipid interactions of amyloidogenic proteins in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35260865/)